Doyle John Brendan
Chief Financial Officer
Doyle John Brendan has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: May 4, 2026.
On the most recent filing, Doyle John Brendan is listed as Chief Financial Officer at COGNITION THERAPEUTICS INC. Inside the rolling window, Doyle John Brendan reported 1 open-market purchase totaling $11K in CGTX and no open-market sales.
Companies traded
Other insiders at CGTX
Insider Buying
$11K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Doyle John Brendan made?
Doyle John Brendan has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Doyle John Brendan trade?
Doyle John Brendan has filed SEC Form 4 disclosures for 1 company, including CGTX.
When was Doyle John Brendan's most recent SEC Form 4 filing?
Doyle John Brendan's most recent SEC Form 4 filing on Tracefour is dated May 4, 2026.
What is Doyle John Brendan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Doyle John Brendan is listed as Chief Financial Officer.
What is Doyle John Brendan's total buy and sell value in the current window?
Inside the rolling retention window, Doyle John Brendan bought $11K and sold $0 based on SEC Form 4 filings.
What was Doyle John Brendan's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 10,000 CGTX shares on 2026-04-16, worth $11K, per SEC Form 4 filings.